EP1353937A4 - SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY - Google Patents

SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY

Info

Publication number
EP1353937A4
EP1353937A4 EP01994329A EP01994329A EP1353937A4 EP 1353937 A4 EP1353937 A4 EP 1353937A4 EP 01994329 A EP01994329 A EP 01994329A EP 01994329 A EP01994329 A EP 01994329A EP 1353937 A4 EP1353937 A4 EP 1353937A4
Authority
EP
European Patent Office
Prior art keywords
human antibodies
cancer therapy
specific human
selective cancer
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01994329A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1353937A2 (en
Inventor
Yocheved Hagai
Janette Lazarovits
Rachel Guy
Orly Lipschitz
Esther Szanton
Avigdor Levanon
Daniel Plaksin
Tuvia Peretz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of EP1353937A2 publication Critical patent/EP1353937A2/en
Publication of EP1353937A4 publication Critical patent/EP1353937A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP01994329A 2000-12-29 2001-12-31 SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY Withdrawn EP1353937A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US751181 2000-12-29
PCT/US2001/049440 WO2002059264A2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Publications (2)

Publication Number Publication Date
EP1353937A2 EP1353937A2 (en) 2003-10-22
EP1353937A4 true EP1353937A4 (en) 2005-04-13

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01994329A Withdrawn EP1353937A4 (en) 2000-12-29 2001-12-31 SPECIFIC HUMAN ANTIBODIES FOR SELECTIVE CANCER THERAPY

Country Status (15)

Country Link
EP (1) EP1353937A4 (enExample)
JP (1) JP2004524023A (enExample)
KR (1) KR20030091952A (enExample)
CN (1) CN100374456C (enExample)
AU (1) AU2002246737B2 (enExample)
BR (1) BR0116763A (enExample)
CA (1) CA2433227A1 (enExample)
CZ (1) CZ20031983A3 (enExample)
HU (1) HUP0400775A2 (enExample)
IL (1) IL156690A0 (enExample)
MX (1) MXPA03005944A (enExample)
NZ (1) NZ527173A (enExample)
PL (1) PL365758A1 (enExample)
RU (1) RU2316564C2 (enExample)
WO (1) WO2002059264A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005101622A (ru) * 2002-07-01 2006-01-27 Савиент Фармасьютикалс, Инк (Us) Композиции и способы терапевтического лечения
CA2531283A1 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
CA2747154C (en) 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
US20160115247A1 (en) * 2014-10-23 2016-04-28 Singh Biotechnology, Llc Single domain antibodies directed against intracellular antigens
WO2016100533A2 (en) * 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
US12509530B2 (en) 2015-08-27 2025-12-30 Singh Moelcular Medicine, LLC Single domain antibodies directed against intracellular antigens
CA2998270A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
FI3377103T4 (fi) * 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
PE20241349A1 (es) * 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
JP2022504802A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
CN116333100A (zh) * 2022-10-31 2023-06-27 南京欧凯生物科技有限公司 一种重组人的lgM抗体快速纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031394A2 (en) * 1997-01-22 1998-07-23 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ADAMS G P ET AL: "Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu", BRITISH JOURNAL OF CANCER, vol. 77, no. 9, May 1998 (1998-05-01), pages 1405 - 1412, XP009037431, ISSN: 0007-0920 *
DE KRUIF J ET AL: "New perspectives on recombinant human antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 17, no. 10, 1 October 1996 (1996-10-01), pages 453 - 455, XP004034704, ISSN: 0167-5699 *
DE KRUIF J ET AL: "Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, no. 9, 25 April 1995 (1995-04-25), pages 3938 - 3942, XP002149535, ISSN: 0027-8424 *
HOOGENBOOM H R ET AL: "Antibody phage display technology and its applications", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 4, no. 1, 1 June 1998 (1998-06-01), pages 1 - 20, XP004127382, ISSN: 1380-2933 *
HOOGENBOOM H R: "Designing and optimizing library selection strategies for generating high-affinity antibodies", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 15, no. 2, 1 February 1997 (1997-02-01), pages 62 - 70, XP004034115, ISSN: 0167-7799 *
HUDSON P J ET AL: "High avidity scFv multimers; diabodies and triabodies", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 177 - 189, XP004186084, ISSN: 0022-1759 *
NISSIM A ET AL: "ANTIBODY FRAGMENTS FROM A 'SINGLE POT' PHAGE DISPLAY LIBRARY AS IMMUNOCHEMICAL REAGENTS", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 3, 1994, pages 692 - 698, XP002926488, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
EP1353937A2 (en) 2003-10-22
KR20030091952A (ko) 2003-12-03
IL156690A0 (en) 2004-01-04
WO2002059264A3 (en) 2003-03-06
CN1551886A (zh) 2004-12-01
HUP0400775A2 (en) 2007-05-02
PL365758A1 (en) 2005-01-10
MXPA03005944A (es) 2005-04-29
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
BR0116763A (pt) 2004-03-09
NZ527173A (en) 2006-03-31
CA2433227A1 (en) 2002-08-01
RU2003123100A (ru) 2005-03-10
CZ20031983A3 (cs) 2005-07-13
JP2004524023A (ja) 2004-08-12
RU2316564C2 (ru) 2008-02-10
WO2002059264A2 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
IL156690A0 (en) Specific human antibodies for selective cancer therapy
GB2386120B (en) Differentiated cells suitable for human therapy
EP1572131A4 (en) ANTIBODY THERAPY
TWI347951B (en) Therapeutic human anti-il-1r1 monoclonal antibody
GB0028429D0 (en) Therapy
AU2001282717A1 (en) Cancer treatment by combination therapy
AU2001251348A1 (en) Apparatus for sensing human prostate tumor
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
GB2367993B (en) Radiotherapy apparatus
AU2002351374A8 (en) Antibodies to treat cancer
AU144325S (en) Therapy device
GB0001710D0 (en) Therapeutic treatment
GB0005257D0 (en) Breast cancer hormonal therapy
GB2374018B (en) Ultrasound therapy
AU2096002A (en) Therapeutic treatment
GB0026015D0 (en) Cancer treatment
HK1060133A (en) Specific human antibodies for selective cancer therapy
GB0022216D0 (en) Human FAP-a-specific antibodies for use in cancer therapy
EP1463511A4 (en) COMBINATORY ANTICANCER THERAPY
SI1157041T1 (sl) Protitelesa za terapijo in diagnozo raka
GB0024673D0 (en) Therapeutic antibodies
GB9914057D0 (en) Antibody therapy
GB9927698D0 (en) Therapeutic antibody
GB0015215D0 (en) Tumour therapy
GB0029577D0 (en) Therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030728

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1060133

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SAVIENT PHARMACEUTICALS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20050225

17Q First examination report despatched

Effective date: 20080121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080603

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1060133

Country of ref document: HK